Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms

被引:113
作者
Yasar, U
Lundgren, S
Eliasson, E
Bennet, A
Wiman, B
de Faire, U
Rane, A [1 ]
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Pharmacol, Stockholm, Sweden
[2] Karolinska Hosp, Dept Cardiol, Cardiovasc Lab, S-10401 Stockholm, Sweden
[3] Karolinska Inst, Dept Environm Med, Div Cardiovasc Epidemiol, Stockholm, Sweden
[4] Karolinska Hosp, Dept Surg Sci, Div Blood Coagulat Res, S-10401 Stockholm, Sweden
关键词
CYP2C8; CYP2C9; genetic linkage; polymorphism;
D O I
10.1016/S0006-291X(02)02592-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 (CYP) 2C8 and 2C9 are polymorphic enzymes. The CYP2C8*3 and CYP2C9*2 are the major variant alleles in Caucasian populations. The enzymes encoded by these variant alleles have impaired function for the metabolism of several drug substrates. In the present study 1468 subjects that were used as population-based controls in the Stockholm Heart Epidemiology Program (SHEEP) were genotyped by allelic discrimination using a 5'-nuclease assay for CYP2C8*1, 2C8*3, 2C9*1, 2C9*2, and 2C9*3 variant alleles in which the frequencies appeared to be 0.91, 0.095, 0.83, 0.11, and 0.066, respectively. Approximately, 96% of the subjects with CYP2C8*3 allele also carried a CYP2C9*2 and 85% of the subjects that had, CYP2C9*2 variant also carried a CYP2C8*3. The number of subjects carrying both of the CYP2C8*1*3 and CYP2C9*1*2 was 4.5-fold higher than expected. This strong association may be of importance especially for the metabolism of common substrates of CYP2C8 and CYP2C9 like arachidonic acid that produces physiologically active metabolites. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:25 / 28
页数:4
相关论文
共 17 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
    Dai, D
    Zeldin, DC
    Blaisdell, JA
    Chanas, B
    Coulter, SJ
    Ghanayem, BI
    Goldstein, JA
    [J]. PHARMACOGENETICS, 2001, 11 (07): : 597 - 607
  • [3] Endothelium-derived hyperpolarizing factor synthase (cytochrome P4502C9) is a functionally significant source of reactive oxygen species in coronary arteries
    Fleming, I
    Michaelis, UR
    Bredenkötter, D
    Fisslthaler, B
    Dehghani, F
    Brandes, RP
    Busse, R
    [J]. CIRCULATION RESEARCH, 2001, 88 (01) : 44 - 51
  • [4] Cytochrome P4502C9 (CYP2C9) allele frequencies in canadian native indian and inuit populations
    Gaedigk, A
    Casley, WL
    Tyndale, RF
    Sellers, EM
    Jurima-Romet, M
    Leeder, JS
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (10) : 841 - 847
  • [5] Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    Goldstein, JA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 349 - 355
  • [6] Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian
    Inoue, K
    Yamazaki, H
    Shimada, T
    [J]. XENOBIOTICA, 1998, 28 (04) : 403 - 411
  • [7] Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin
    Kidd, RS
    Curry, TB
    Gallagher, S
    Edeki, T
    Blaisdell, J
    Goldstein, JA
    [J]. PHARMACOGENETICS, 2001, 11 (09): : 803 - 808
  • [8] Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
    Kirchheiner, J
    Brockmöller, J
    Meineke, I
    Bauer, S
    Rohde, W
    Meisel, C
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (04) : 286 - 296
  • [9] Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: Results from the Stockholm Heart Epidemiology Program (SHEEP)
    Leander, K
    Hallqvist, J
    Reuterwall, C
    Ahlbom, A
    de Faire, U
    [J]. EPIDEMIOLOGY, 2001, 12 (02) : 215 - 221
  • [10] Allelic discrimination using fluorogenic probes and the 5′ nuclease assay
    Livak, KJ
    [J]. GENETIC ANALYSIS-BIOMOLECULAR ENGINEERING, 1999, 14 (5-6): : 143 - 149